LBRX LB Pharmaceuticals Inc Common Stock logo

LBRX LB Pharmaceuticals Inc Common Stock

Healthcare
$28.31+0.00%OpenMarket Cap: $811.8M

As of 2026-05-26

Valuation

View Details

P/E (TTM)

PEG

P/B

2.10

P/S

0.00

EV/EBITDA

-10.59

DCF Value

$9.67

FCF Yield

-6.4%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-17.7%

ROA

-10.0%

ROIC

-12.2%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$0.00$-19.1M$
Q4 null$0.00$-11.5M$
FY null$0.00$-25.2M$
Q3 null$0.00$-3.6M$

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$39.50

Target (Median)

$38.50

Target Range

$36.00 - $45.00

1 Strong Buy5 Buy0 Hold0 Sell0 Strong Sell
StifelBuy
2026-03-27
StifelBuy
2025-12-11

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

Beta

1.38

Clinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride.

Peers